Adams Clinical Expands into Inpatient Psychiatry and Schizophrenia Trials via InSite Partnership
Key Insights
Adams Clinical (search) partners with InSite Clinical Research (search), expanding its expertise into inpatient psychiatry and schizophrenia (search) clinical trials, marking its entry into Texas.
The expansion includes adding inpatient capabilities to Adams Clinical (search)'s Watertown, MA, and Bronx, NY sites, expected to begin screening participants in early 2025.
The collaboration aims to address the significant unmet need for effective new therapies for schizophrenia (search) and other psychiatric illnesses.
Adams Clinical (search), a neuroscience-focused clinical trial site network, has announced a partnership with InSite Clinical Research (search), a clinical trial site located in the Dallas-Fort Worth area. This collaboration marks Adams Clinical's expansion into inpatient psychiatry and schizophrenia (search) clinical trials, as well as its entry into the Texas market.
Strategic Expansion
In conjunction with the partnership, Adams Clinical (search) is also expanding inpatient capabilities at its existing sites in Watertown, MA, and Bronx, NY. Both locations are anticipated to begin screening inpatient participants in the first half of 2025. This move will augment Adams Clinical's existing capabilities in outpatient psychiatry and Alzheimer’s disease (search) treatment and prevention trials.
According to Nelson Rutrick, CEO of Adams Clinical (search), "InSite adds an important dimension to our business as it expands Adam’s disease area expertise and marks the Company’s entry into Texas. Historically, Adams Clinical focused only on Depression (search), outpatient Psychiatry, and Alzheimer’s Disease (search). Dr. Shiwach and the entire InSite team are widely regarded by pharmaceutical and biotech industry sponsors as a leader in acute Schizophrenia (search), Bipolar Disorder (search) and Substance Use Disorder (search) research."
Addressing Unmet Needs in Schizophrenia
The partnership aims to address the significant unmet need for effective new therapies for individuals living with schizophrenia (search) and other psychiatric illnesses. Dr. Steve Brannan, an industry veteran in schizophrenia drug development, noted that "There continues to be an enormous unmet need for effective new therapies for people living with Schizophrenia and other psychiatric illnesses. The many promising new treatments in development across industry will necessitate an increase in clinical research sites capable of conducting high-quality inpatient and outpatient Psychiatry trials for the foreseeable future."
Dr. Raj Shiwach, Principal Investigator at InSite, expressed his enthusiasm for the partnership, stating, "I am delighted to join the Adams Clinical (search) network and bring opportunities for additional clinical trials to the diverse psychiatric and neurological patient population that we serve here in Texas. I look forward to sharing my clinical expertise to replicate our successful inpatient Schizophrenia (search) trial delivery model in the Massachusetts and New York locations."
About InSite Clinical Research
InSite Clinical Research (search) has a strong track record in conducting inpatient and outpatient clinical trials for psychiatric and neurological illnesses, including schizophrenia (search), bipolar disorder (search), and substance use disorder (search). The company is known for its contributions to successful clinical trials that have led to new drug approvals over the past 20 years.
Adams Clinical's Continued Growth
The partnership with InSite follows a series of strategic expansion steps Adams Clinical (search) has undertaken in 2024, including doubling existing site capacity with the opening of new site locations in New York City with Davis Clinical in the Bronx and Berman Clinical in Harlem.